华熙生物科技股份有限公司 关于控股股东增持股份进展暨增持金额超过区间下限的公告

Core Viewpoint - The controlling shareholder of Huaxi Biotechnology Co., Ltd. plans to increase its stake in the company, reflecting confidence in the company's future development and long-term investment value [2]. Summary by Sections Shareholder Buyback Plan - Huaxi Xinyu Investment Co., Ltd., the controlling shareholder, intends to increase its stake in Huaxi Biotechnology starting from August 8, 2025, for a period of six months, with a planned investment of no less than RMB 200 million and no more than RMB 300 million [2]. - The buyback will not exceed 1% of the company's total share capital, and the purchase price will not exceed RMB 70 per share [2]. Implementation Status - As of September 5, 2025, Huaxi Xinyu has acquired 3,496,931 shares, representing 0.73% of the total share capital, with a total expenditure of approximately RMB 200.68 million, surpassing the lower limit of the planned investment [2]. Risks Related to the Buyback Plan - There are potential risks that the buyback plan may not be implemented as expected due to changes in the capital market or other unpredictable factors [3][4].